Review Article

Cellular Dysfunction in Diabetes as Maladaptive Response to Mitochondrial Oxidative Stress

Alba Naudi, Mariona Jove, Victoria Ayala, Anna Cassanye, Jose Serrano, Hugo Gonzalo, Jordi Boada, Joan Prat, Manuel Portero-Otin, and Reinald Pamplona

Department of Experimental Medicine, Faculty of Medicine, University of Lleida-IRBLleida, 25008 Lleida, Spain

Correspondence should be addressed to Reinald Pamplona, reinald.pamplona@mex.udl.cat

Received 28 July 2011; Accepted 27 September 2011

Academic Editor: Robert A. Harris

Copyright © 2012 Alba Naudi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Oxidative stress has been implicated in diabetes long-term complications. In this paper, we summarize the growing evidence suggesting that hyperglycemia-induced overproduction of superoxide by mitochondrial electron transport chain triggers a maladaptive response by affecting several metabolic and signaling pathways involved in the pathophysiology of cellular dysfunction and diabetic complications. In particular, it is our goal to describe physiological mechanisms underlying the mitochondrial free radical production and regulation to explain the oxidative stress derived from a high intracellular glucose concentration and the resulting maladaptive response that leads to a cellular dysfunction and pathological state. Finally, we outline potential therapies for diabetes focused to the prevention of mitochondrial oxidative damage.

1. Introduction

The Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) established that hyperglycemia is the initiating cause of the diabetic tissue damage which is verified clinically [1, 2]. Even though this process is modified by both genetic determinants of individual susceptibility and by independent accelerating factors such as hypertension, both the repeated acute changes in cellular metabolism and cumulative long-term changes in cellular constituents appear to be the mechanisms that mediate the cell-damaging effects of hyperglycemia.

The cell-damaging effects of hyperglycemia comprise the damage to a selective subset of cell types directly involved in diabetic complications: endothelial cells in the vascular system, mesangial cells in the kidney, neurons and neuroglia in the nervous system, and pancreatic β cells. Why are these cells especially vulnerable to hyperglycemic conditions? In the organism, most cells are able to downregulate the transport of glucose inside the cell when they are exposed to a hyperglycemic status, so that their intracellular glucose concentration stays constant. In contrast, the cells injured by hyperglycemia are those that cannot do this efficiently [3, 4], leading to high glucose levels inside the cell. In this scenario, available evidences demonstrate that a hyperglycemia-induced cellular oxidative stress is the basic mechanism underlying the physiopathology of the diabetic complications. Indeed it has been suggested that increased mitochondrial free radicals production during hyperglycemia may be central of the pathology of diabetes [5, 6]. Therefore, mitochondrial free radical production and oxidation-derived molecular damage may contribute to the onset, progression, and pathological consequences of diabetes. Here, we discuss how mitochondrial oxidative damage occurs, consider the maladaptive mechanisms by which it may contribute to the pathophysiology of diabetes, and outline potential therapeutic strategies to prevent it.

2. Physiology of the Mitochondrial Oxidative Damage

Inside mitochondria, electrons from reduced substrates move from complexes I and II of the electron transport chain through complexes III and IV to oxygen, forming water and causing protons to be pumped across the mitochondrial inner membrane. When glucose is metabolized through the tricarboxylic acid (TCA) cycle (or fatty acids through
β-oxidation), it generates electron donors. The main electron donor is NADH, which gives electrons to complex I. The other electron donor generated by the TCA cycle is FADH₂, formed by succinate dehydrogenase, which donates electrons to complex II. The proton motive force set up by proton pumping [7] drives protons back through the ATP synthase in the inner membrane, forming ATP from their precursors ADP (adenosine diphosphate) and phosphate [8]. The electron transport system is organized in this way so that the level of ATP can be precisely regulated.

In this context, a major side reaction is that electrons may leak from the respiratory chain and react with oxygen to form the free radical superoxide. Superoxide anion, the product of a one-electron reduction of oxygen, is the precursor of most reactive oxygen species (ROS) and a mediator in oxidative chain reactions [71–75]. So, oxygen reduction, needed for aerobic life, generates three main ROS, superoxide radical, hydrogen peroxide (H₂O₂), and hydroxyl radical. The hydroxyl radical can be generated by the combination of superoxide radical and H₂O₂ in the presence of traces of iron or copper during the Fenton-Haber-Weiss reaction. Thus, H₂O₂, although it is not a free radical, can work as a Trojan horse, diffusing away from sites of ROS production to generate the hydroxyl and other reactive radicals at other cellular locations, hereby propagating oxidative damage. Other ROS of probable relevance for endothelial cells are the perhydroxyl radical, particularly near membranes where local pH is lower than in the bulk solution [76], singlet oxygen, and nitric oxide. In the case of mitochondria, nitric oxide production is much smaller than superoxide production. However, nitric oxide can still be important due to interaction with superoxide and other radicals to produce reactive nitrogen species like peroxynitrite [77], which can modify many kinds of macromolecules and possibly contribute to diabetes vascular complications [78].

Despite ROS can be generated at various sites and under various conditions (including ischaemia-reperfusion, enzymatic reactions (e.g., the membrane NADPH oxidase, lipoxigenases, cyclooxygenases, peroxidases, and other heme proteins), the enzyme xanthine oxidase, peroxisomes, or the hepatic P-450 microsomal detoxifying system), in healthy cells under physiological conditions, most ROS are originated in mitochondria [79]. Currently, it is well known that mitochondrial ROS generation occurs at complex I [79–86] and at complex III [87, 88]. Concerning the electron transport component responsible for mROS generation within complex I, flavin mononucleotide, ubisemiquinone species, or iron-sulphur clusters have been proposed [89–97].

The finding that the percentage of total electron flow directed to free radical generation in mitochondria is not constant in different tissues and different conditions inside a given tissue suggests that ROS generation is not a simple byproduct of mitochondrial respiration as is frequently assumed. Indeed there is a lack of stoichiometric coupling of ROS production to oxygen consumption [98]. Therefore, it should be better viewed as a homeostatically controlled variable.

**Figure 1:** Uncoupling proteins (UCPs) respond to hyperglycemia-induced overproduction of mitochondrial superoxide by catalyzing mild uncoupling, which lowers membrane potential (ΔΨm) and decreases superoxide production by mitochondrial complex I and III of the electron transport chain. Antioxidants limit the impact of superoxide production on molecular oxidative damage (for more details, see text). MS: mitochondrial redox shuttles; O₂*: superoxide radical; PT: pyruvate transporter; TCA: tricarboxylic acid cycle.

Are there physiological adaptation mechanisms with ability to modulate the rate of mitochondrial free radical generation? Available evidence seems to suggest that this is the case [99]. Among these adaptations, two negative feedback loops protect cells from ROS-induced damage. The first mechanism is characterized by regulation of uncoupling proteins (UCPs). During oxidation of substrates, the complexes of the mitochondrial electron transport chain reduce oxygen to water and pump protons into the intermembrane space, forming a proton motive force (Δp). However, some electrons in the reduced complexes also react with oxygen to produce superoxide. Superoxide can peroxidize membrane phospholipids, forming hydroxynonenal, which induces proton transport through the UCPs and the adenine nucleotide translocase. The mild uncoupling caused by proton transport lowers Δp and slightly stimulates electron transport, causing the complexes to become more oxidized and lowering the local concentration of oxygen; both these effects decrease superoxide production. Thus, the induction of proton leak by hydroxynonenal limits mitochondrial ROS production as a feedback response to overproduction of superoxide by the respiratory chain [89, 100, 101]. So, a possible antioxidant physiological function for UCPs has been proposed [100]. In this model, UCPs respond to overproduction of matrix superoxide by catalyzing mild uncoupling, which lowers proton motive force and would decrease superoxide production by the electron transport chain (Figure 1).

The second feedback loop consists of a regulation of the flux of metabolites to mitochondria. So, a transient overproduction of ROS by the mitochondrial electron transport chain is associated with a decrease of these fluxes. A change of the substrate availability to oxidative phosphorylation is thus a negative feedback controlling ROS production.
transport chain can decrease the activity of the key glycolytic enzyme glyceraldehyde-3 phosphate dehydrogenase (GAPDH) by modifying the enzyme by ADP-ribosylation [102]. Poly(ADP-ribosyl)ation represents an immediate cellular response to DNA damage induced by oxidants [103–105]. In the absence of DNA single and double-strand breaks, poly(ADP-ribosyl)ation is a very rare event, but it can increase over 100-fold upon DNA damage. Under these conditions, about 90% of poly(ADP-ribose) is synthesized by poly(ADP-ribose) polymerase 1 (PARP-1). PARP-1 is constitutively expressed but enzymatically activated by DNA strand breaks. So, PARP-1 functions as a DNA damage sensor and signaling molecule binding to both single- and double-stranded DNA breaks. It catalyses the formation of ADP-ribose from the oxidized form of nicotinamide adenine dinucleotide (NAD+) by cleavage of the glycosidic bond between nicotinamide and ribose. Glutamate, aspartate, and carboxyterminal lysine residues of target (“acceptor”) proteins are then covalently modified by the addition of an ADP-ribose subunit, via formation of an ester bond between the protein and the ADP-ribose residue. So, poly(ADP-ribosyl)ation is a covalent posttranslational protein modification linked with genome protection [103, 106]. In this scenario, it is plausible to suggest that the inhibitory effect of ADP-ribosylation on GAPDH probably represents a feedback loop in order to reduce levels of glycolysis and transiently block the subsequent flux of metabolites to mitochondria allowing a decrease in the levels of reducing equivalents and the subsequent mitochondrial ROS production and oxidative cellular molecular damage (Figure 2).

3. Mitochondrial Antioxidant Defenses

Oxidative stress homeostasis (e.g., balance between ROS production and elimination) relies on endogenous cellular antioxidants [99, 107–109]. Mitochondria, from an intracellular organelle comparative approach, are endowed with the best antioxidants, detoxifying and repair systems against oxidative damage. So, the antioxidant enzyme MnSOD (manganese superoxide dismutase) converts superoxide to H2O2. The mitochondrial isoform of glutathione peroxidase (GPx) and the thioredoxin-dependent enzyme peroxiredoxin III both detoxify H2O2; alternatively, H2O2 can diffuse from the mitochondria into the cytoplasm. The mitochondrial glutathione (GSH) pool is different from that in the cytosol and is maintained in its reduced state by a mitochondrial isoform of glutathione reductase (GR). This enzyme requires NADPH, which is produced within mitochondria by the NADP-dependent isocitrate dehydrogenase and through a proton electrochemical potential gradient-dependent transhydrogenase. Within the mitochondrial phospholipid bilayer, the fat-soluble antioxidants vitamin E and coenzyme Q (CoQ) both prevent lipid peroxidation, while CoQ also recycles vitamin E and is itself regenerated by the respiratory chain. The mitochondrial isoform of phospholipid hydroperoxide glutathione peroxidase [110] degrades lipid peroxides within the mitochondrial inner membrane. There are also a variety of specific mitochondrial mechanisms to repair or degrade oxidatively damaged lipids [108, 110], proteins [111], and mtDNA [112].

4. Hyperglycemia Induces Permanent Overproduction of Superoxide by Mitochondrial Electron Transport Chain

As mentioned above, the major sites of ROS generation are the complexes I and III of the mitochondrial electron transport chain. In cells under sustained high glucose concentrations, there is more glucose being oxidized in the TCA cycle. This situation drives to pushing more electron donors (NADH and FADH2) into the electron transport chain thus leading to an increase in ROS generation [5, 6]. This is so
because in this situation, there is a higher degree of reduction of complexes I and III increasing their rate of ROS production. The rate of mitochondrial ROS generation strongly increases with a sigmoidal kinetics when the NADH/NAD+ ratio is increased, because this dramatically increases the degree of reduction of the complex I ROS generator [84, 98]. In an identical way, in the insulin resistance syndrome, there is an increased free fatty acid (FFA) flux from adipocytes into arterial endothelial cells that might result in increased FFA oxidation by the mitochondria. Since both β-oxidation of fatty acids and oxidation of FFA-derived acetyl CoA by the TCA cycle generate the same electron donors (NADH and FADH2) generated by glucose oxidation, increased FFA oxidation may cause mitochondrial overproduction of ROS [113] by exactly the same mechanism described above for hyperglycemia, and in both cases can be reversed upon exposure to agents that act as mitochondrial uncouplers or electron transport chain inhibitors.

Concomitantly with the hyperglycemia-induced mitochondrial free radical overproduction, it has been described that in hyperglycemia Ucp2 gene transcription is activated by key regulatory proteins such as peroxisome proliferator-activated receptors (PPARs), forkhead transcription factors, sterol regulatory element-binding protein-1c (SREBP-1c) [114], and AMP-activated protein kinase [115]. Additionally, the pathological and persistent overproduction of ROS by the mitochondrial electron transport chain decreases the activity of the key glycolytic enzyme GAPDH. The inhibition of GAPDH activity by “hyperglycemia” does not occur when mitochondrial overproduction of superoxide is prevented by either UCP1 or MnSOD [116]. In addition, subsequent studies demonstrate that persistent high intracellular glucose concentration-induced superoxide inhibits GAPDH activity in vivo by modifying the enzyme by ADP-ribosylation [102]. By inhibiting mitochondrial superoxide production with either UCP-1 or MnSOD, it prevented the modification of GAPDH by ADP-ribose and the reduction of its activity. Most importantly, the modification of GAPDH is prevented by a specific inhibitor of poly(ADP-ribose) polymerase (PARP), the enzyme that makes these polymers of ADP-ribose, establishing a cause-and-effect relationship between PARP activation and the changes in GAPDH [5]. Therefore, this mechanism seems to indicate that the stress-induced block of glycolysis is not the result of a passive oxidative damage but rather an active cell adaptation programmed via ADP-ribosylation for cell self-defence.

However, the chronic increase in target cells of the intracellular glucose concentration and permanent block of glycolysis leads to a maladaptive response derived from the upstream accumulation of glycolytic metabolites which are substrates for the activation of metabolic pathways involved in the development of diabetic complications. In addition to this maladaptive response, the block of glycolysis leads to a fall of mitochondrial substrates that originates a reduced mitochondrial energy production and subsequent cell exhaustion that can be a determinant element in the endothelial cell dysfunction. In this scenario, other cellular sources of free radical generation could take the relief to mitochondria assuming a relevant role in a potential second round of cellular oxidative molecular damage.

5. Hyperglycemia-Induced Mitochondrial Free Radical Generation Activates Damaging Downstream Cellular Pathways

From the scenario described above, it was proposed that different pathogenic mechanisms leading to the development of diabetic complications do reflect a single hyperglycemia-induced process [5]. This process is based on that hyperglycemia, through the overproduction of free radicals by the mitochondrial electron transport chain, decreases the activity of the key glycolytic enzyme GAPDH. So, when GAPDH activity is inhibited, the level of all the glycolytic intermediates located upstream of GAPDH increases. Increased levels of the upstream glycolytic metabolite glyceraldehyde-3-phosphate activate two pathogenic pathways: (a) it activates the glycation pathway because methylglyoxal, a glycation precursor, is formed from glyceraldehyde-3-phosphate [117–119], and (b) it also activates the protein-kinase C pathway because diacylglycerol, one of its activators, is also formed from glyceraldehyde-3-phosphate [102, 120]. Further upstream, levels of the glycolytic metabolite fructose-6-phosphate increase, which increases flux through the hexosamine pathway, where fructose-6-phosphate is converted by the enzyme GFAT to UDP-N-acetylglucosamine (UDP-GlcNac) increasing the chances for hexosamine modification of proteins [116]. Finally, inhibition of GAPDH increases intracellular levels of the first glycolytic metabolite, glucose. This increases flux through the polyol pathway, where the enzyme aldose reductase reduces it, consuming NADPH in the process and reducing available GSH [120–123].

Besides these maladaptive damaging cellular pathways, it must be considered the cellular responses derived from the PPAR overactivation as important mechanism of tissue damage also leading to an endothelial dysfunction in diabetic blood vessels, which importantly contributes to the development of various diabetic complications. Thus, PPAR activation, in addition to the mitochondrial bioenergetic depletion due to the block of glycolysis, potentiates in a maladaptive process the expression of various proteins at the transcriptional level [124]. Of special importance is the regulation by PARP-1 of the production of inflammatory mediators such as inducible nitric oxide synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), and major histocompatibility complex class II. NF-κB is a key transcription factor in the regulation of this set of proteins, and PARP has been shown to act as a coactivator in the NF-κB-mediated transcription. Poly(ADP-ribose)lation can loosen up the chromatin structure, thereby making genes more accessible for the transcriptional machinery [118]. Therefore, all these metabolic pathways originate alterations in gene expression, inflammatory responses, and structural and functional changes in cellular constituents that also participate in the molecular basis of the vascular diabetic process (Figure 3).
Experimental Diabetes Research

Hyperglycaemia

Target cell

↑ Intracellular glucose concentration

Mitochondrial oxidative stress

Block of glycolytic flux

↑ Reducing equivalents

↑ Glycolytic intermediates

Mitochondrial bioenergetic depletion

↑ Polyol pathway flux

↑ Advanced glycation end products

↑ Advanced glycation end products

↑ Protein kinase C

↑ Hexosamine pathway flux

↑ Molecular damage and oxidative stress

↑ Inflammatory responses

Changes gene expression

---

6. Protein Oxidative Damage: Protein Carbonyl Content in Diabetes

Oxidative damage occurs whenever the ROS produced by mitochondria evade detoxification, and the steady-state level of molecular oxidative damage depends on the relative rates of damage accumulation, repair, and degradation. ROS can damage all types of biomolecules, and oxidative damage to DNA, lipids and proteins can be deleterious and concomitant [107]. The primary cellular target of oxidative stress depends upon the cell type, the nature of the stress imposed, the susceptibility to oxidation of the target molecule, the site of generation, the proximity of ROS to a specific target, and the severity of the stress. In this context, protein oxidation demands an especial mention because proteins constitute the major “working force” for all forms of biological work. Furthermore, their exact conformation and pattern of folding are tightly related to their activity and function. So, the consequent loss of function and structural integrity of modified proteins can have a wide range of downstream functional consequences and may be the cause of subsequent cellular dysfunctions and tissue damage (Table 1). The products of oxidation of amino acids are indicators of modification to proteins in biological systems [125–129]. They include oxidized amino acids, modified amino acids by reactive nitrogen species and chlorination reactions, and crosslinks formed by a combination of enzymatic and nonenzymatic mechanisms.

Amino acid residues in proteins are highly susceptible to oxidation by one or more reactive species. Many different types of protein oxidative modification can be induced directly by ROS or indirectly by reactions of secondary byproducts of oxidative stress (basically derived from the oxidation of both carbohydrates and polyunsaturated fatty acids that lead to the formation of the named reactive carbonyl species, RCOs [130]). Cysteine and methionine are particularly prone to oxidative attack by almost all ROS. Protein modifications are elicited by direct oxidative attack on Lys, Arg, Pro, or Thr, or by secondary reaction of Cys, His or Lys residues with reactive carbonyl compounds can lead to the formation of protein carbonyl (PCO) derivatives (aldehydes and ketones) [125, 130, 131] (Table 2).

---

**Table 1: Effects of oxidative damage in protein structure and function.**

(i) Cleavage of peptide bonds
(ii) Direct reaction of proteins with ROS can lead to formation of protein derivatives or peptide fragments possessing highly reactive carbonyl groups (ketones, aldehydes)
(iii) Formation of intra- or interprotein cross-linked derivatives that can lead to the formation of aggregates by (a) direct interaction of two carbon-centered radicals; (b) interaction of two tyrosine radicals; (c) oxidation of cysteine sulfhydryl groups; (d) interactions of the carbonyl groups of oxidized proteins with the primary amino groups of lysine residues in the same or a different protein; (e) by noncovalent interactions such as hydrophobic and electrostatic interactions between oxidized residues
(iv) Partial unfolding or denaturation with a concomitant increase in surface hydrophobicity
(v) Loss of function (e.g., enzyme activity)
Studies of the formation of PCOs cannot differentiate between those produced through direct protein oxidation and those formed by the addition of previously oxidized molecules, and hence protein carbonyl content (PCC) must be considered as a broad and unspecific marker of oxidation. Because carbonyls are relatively difficult to induce compared with, for example, methionine sulfoxide and cysteinylderivatives, they might indicate a more rigorous oxidative stress. Indeed, elevated levels of PCC are generally a sign not only of oxidative stress, but also of disease-derived protein dysfunction. PCC can have an advantage over both carbohydrate and lipid oxidation products as markers of oxidative stress; oxidized proteins are generally more stable. PCCs form early and circulate in the blood for longer periods (their elevation in serum is stable for at least four hours), compared with other parameters of oxidative stress, such as glutathione disulphide and malondialdehyde [131]. The PCC seems to be a common phenomenon during oxidation-derived protein damage, and their quantification can be used to measure the extent of chemical and nonenzymatic oxidative modification. This has driven the development of various sensitive but unspecific biochemical (spectrophotometric and fluorometric) and immunological (western blot, enzyme-linked immunosorbent assay (ELISA), and proteomics) methods for the detection and measurement of the PCC in tissues and body fluids; in all of them 2,4-dinitrophenylhydrazine is allowed to react with the PCOs to form the corresponding hydrazone, which can be analyzed by the above mentioned methods. Currently, PCC is the most general indicator and by far the most commonly used marker of protein oxidation. Because the mechanisms of PCC generation are nonspecific, it has been argued that other protein modifications, such as the conversion of tyrosine residues to 3-chlorotyrosine, 3-nitrotyrosine or dityrosine, arginine and proline to glutamic semialdehyde, or lysine to aminoadipic semialdehyde, are better markers of oxidative stress. However, the tissue levels of such markers are orders of magnitude lower than the overall PCC and, hence, their measurement often requires highly sensitive and expensive methods such as mass spectrometry [109, 130, 132].

Tables 3 and 4 summarize available studies where PCC was analyzed by different methods in the diabetic status. From this summary of the effects of diabetes on PCC, it is possible to propose some general ideas: (1) Mouse, rabbit, and especially rat are the animal species used as reference for the study of the effects of experimental diabetes, being the STZ-induced diabetes the experimental model predominantly, but not exclusively, used. (2) PCC levels are consistently increased in all the analyzed tissues independently of the analytical method used. Of particular interest are the increased PCC levels showed by the organs containing the selective subset of cell types directly involved in diabetic complications: vascular system, kidney, brain, and pancreas. (3) In humans, most studies are focused to Type 2 diabetes and the measurement of PCC in plasma proteins. (4) In humans, elevated PCC levels have been detected in both Type 1 and Type 2 diabetes. (5) Plasma PCC levels are significantly higher in diabetic children and adolescents without complications compared with control

| Amino acid | Product |
|------------|---------|
| (i) Arginine | Glutamic-semialdehyde |
| (ii) Cysteine | Cysteine disulfides, Sulmonic acid, Asparagine |
| (iii) Histidine | Asparagine, 2-Oximiodazoline, 2-Oxohistidine |
| (iv) Leucine | 3-, 4-, 5-Monohydroxyleucine |
| (v) Leucine, valine, isoleucine, proline, and others | Protein carbonyls |
| (vi) Lysine | 2-Amino-adipic-semialdehyde |
| (vii) Methionine | Methionine sulfoxide |
| (viii) Phenylalanine | ortho- and meta-tirosine |
| (ix) Proline | Glutamate |
| (x) Threonine | Glutamic-semialdehyde |
| (xi) Tryptophan | 2-Amino-3-ketobutyric acid |
| (xii) Tyrosine | 2-Pyrollidone |

Glutamic semialdehyde is a product of oxidation of arginine and proline, and aminoadipic semialdehyde, of oxidation of lysine. They account for 55–100% of the total carbonyl value in several metal ion-catalyzed oxidation (MCO) systems [128, 132]. Sensitive gas chromatography-mass spectrometry based analytical methods have allowed their quantitation in a variety of biological samples providing specific information on the oxidative status of proteins that is complementary to that afforded by protein carbonyls, and will be useful tools in the ongoing effort to define and assess the role of protein oxidation in diabetes complications [95, 132].

Other oxidation-derived protein damage markers include protein modifications derived from reactive nitrogen species (RNS). Nitric oxide generated from nitric oxide synthetases plays an important role in the regulation of various physiological parameters (very especially at the vascular level) but due to its free radical nature, it could also react with superoxide radical to form highly reactive peroxynitrite functions [133]. It has been established that aromatic amino acids, cysteine, and methionine residues of proteins are particularly sensitive to modification by RNS. These reactions lead to nitration of tyrosine residues of proteins [134, 135], the oxidation of methionine residues to methionine sulfoxide, and the nitrosation of protein sulfhydryl groups to RSNO derivatives [136–138].
Table 3: Effects of experimental diabetes in levels of protein carbonyls.

| Tissue                  | Model                                      | Effect | Reference |
|-------------------------|--------------------------------------------|--------|-----------|
| Aorta                   | BKS.cg-m +/+ Lepr db/J mice versus wild type | 1      | [9]       |
| Hippocampus and cerebral cortex | Streptozotocin | 1      | [10]      |
| Kidney                  | Type 2 diabetic db/db versus normoglycemic wild type mouse | 1      | [11]      |
| Lenses                  | Streptozotocin                             | 1      | [12]      |
| Aorta                   | Goto-Kakizaki rats                         | 1      | [13]      |
| Bone                    | Goto-Kakizaki rats                         | 1      | [14]      |
| Brain                   | Galactose-induced hyperglycemia            | 1      | [15]      |
| Brain                   | Goto-Kakizaki rats                         | 1      | [16]      |
| Brain                   | Streptozotocin                             | 1      | [17]      |
| Heart                   | Streptozotocin                             | 1      | [18]      |
| Heart                   | Streptozotocin                             | 1      | [19]      |
| Heart                   | Streptozotocin                             | 1      | [20]      |
| Heart                   | Streptozotocin                             | 1      | [21]      |
| Heart                   | Streptozotocin                             | 1      | [17]      |
| Hemoglobin              | Streptozotocin                             | 1      | [22]      |
| Intestinal tissue       | Streptozotocin                             | 1      | [23]      |
| Kidney                  | Streptozotocin                             | 1      | [24]      |
| Kidney                  | Streptozotocin                             | 1      | [18]      |
| Kidney                  | Zucker obese hyperglycemic rats (ZDFn Gm-fa/fa) | 1      | [25]      |
| Kidney                  | Streptozotocin                             | 1      | [26]      |
| Kidney                  | Streptozotocin                             | 1      | [17]      |
| Lens proteins           | Streptozotocin                             | 1      | [27]      |
| Liver                   | Streptozotocin                             | 1      | [24]      |
| Liver                   | Pregnant diabetic rats versus control rats | 1      | [28]      |
| Liver                   | Galactose-induced hyperglycemia            | 1      | [15]      |
| Liver                   | Streptozotocin                             | 1      | [18]      |
| Liver                   | Streptozotocin                             | 1      | [29]      |
| Liver                   | Streptozotocin                             | 1      | [23]      |
| Liver                   | Streptozotocin                             | 1      | [30]      |
| Liver                   | Streptozotocin                             | 1      | [17]      |
| Lung                    | Streptozotocin                             | 1      | [31]      |
| Pancreas                 | Streptozotocin                             | 1      | [18]      |
| Pancreas                 | Alloxan                                    | 1      | [32]      |
| Pancreas                 | Streptozotocin                             | 1      | [17]      |
| Pancreas                 | Streptozotocin                             | 1      | [33]      |
| Plasma proteins          | Streptozotocin                             | 1      | [34]      |
| Plasma proteins          | Streptozotocin                             | 1      | [35]      |
| Plasma proteins          | Streptozotocin                             | 1      | [36]      |

Table 3: Continued.

| Tissue                  | Model                                      | Effect | Reference |
|-------------------------|--------------------------------------------|--------|-----------|
| Red blood cells         | Streptozotocin                             | 1      | [18]      |
| Retinal Müller cells    | Streptozotocin                             | 1      | [37]      |
| Skeletal muscle         | Glupreclamp infusion versus control        | 1      | [38]      |
| Skeletal muscle         | Otsuka Long Evans Tokushima Fatty (OLETF) rats versus LETO rats | 1      | [39]      |
| Skeletal muscle (Soleus muscles) | Goto-Kakizaki rats        | 1      | [13]      |
| Skeletal muscle (Plantaris muscle) | Obese Zucker rats versus lean Zucker rats | 1      | [40]      |
| Skeletal muscle         | Streptozotocin                             | 1      | [41]      |
| Testis and epididymal sperm | Streptozotocin                         | 1      | [42]      |
| Vascular smooth muscle cells | Glucose incubation                      | 1      | [43]      |
| Heart                   | Alloxan                                    | 1      | [44]      |
| Lens proteins and cells | In vitro incubation                       | 1      | [45]      |

subjects, suggesting that oxidative protein damage occurs at the onset of disease and tends to increase in the later stages. (6) The presence of a diabetic complication is associated with higher PCC levels. (7) There is a lack of studies specifically driven to the vascular system.

7. Current Antioxidant Therapeutic Strategies

Hyperglycemia-induced overproduction of superoxide by mitochondrial electron transport chain induces a cellular maladaptive response that triggers several metabolic pathways of injury involved in the endothelial dysfunction and contributes to the progressive development of micro- and macrovascular complications and multiorgan damage. Consequently, inhibition of mitochondrial oxidant generation and/or oxidative-derived molecular damage might provide a potential approach for the prevention of diabetic vascular complications.

Even though it is well established that good (but strict) glycemic control is the basis for the prevention of diabetic complications, there is no doubt that preventive measures targeting other risk factors should be also achieved. Therapeutic strategies for diabetic vascular complications should consist in the modulation of afflicted pathways. Thus, therapeutic strategies to limit mitochondrial radical production during hyperglycemia and to counteract their damaging effects could be useful complements to conventional therapies designed to normalize blood glucose. As our understanding of molecular mechanisms evolves, it is becoming clear that a more comprehensive approach is needed. Based
Table 4: Effect of diabetes in protein carbonyl content (PCC) levels from human tissues.

| Tissue                  | Model/condition                                         | Effect | Reference |
|-------------------------|---------------------------------------------------------|--------|-----------|
| Erythrocytes            | Obese type 2 diabetic patients                        | ↑      | [46]      |
| Erythrocytes            | Type 2 diabetic patients versus healthy subjects       | ↑      | [47]      |
| Erythrocyte membrane    | Type 2 diabetic patients versus healthy subjects       | ↑      | [48]      |
| Lymphocytes             | Type 2 diabetic patients versus age-matched controls   | ↑      | [49]      |
| Lymphocytes             | DM patients versus healthy subjects                    | ↑      | [50]      |
| Placenta                | Women with gestational diabetes versus healthy pregnant women | ↑      | [51]      |
| Plasma proteins         | Type 2 diabetic patients versus healthy subjects       | ↑      | [52]      |
| Plasma proteins         | Dialysis patients versus control subjects              | ↑      | [53]      |
| Plasma proteins         | Diabetic type 2 patients versus healthy subjects       | ↑      | [54]      |
| Plasma proteins         | Type 1 diabetes without complications                  | ↑      | [55]      |
| Plasma proteins         | Type 1 diabetes with complications                     | ↑      | [55]      |
| Plasma proteins         | Chronic kidney disease patients versus healthy subjects| ↑      | [56]      |
| Plasma proteins         | Diabetes type 2 versus healthy subjects                | ↑      | [57]      |
| Plasma proteins         | Diabetes type 2 associated with CVD versus healthy subjects | ↑      | [57]      |
| Plasma proteins         | Good glycemic control versus poor glycemic control     | ↑      | [58]      |
| Plasma proteins         | Type 1 diabetic patients                               | ↑      | [59]      |
| Plasma proteins         | End-stage renal disease                                | ↑      | [59]      |
| Plasma proteins         | Heart failure + diabetes versus healthy subjects       | ↑      | [60]      |
| Plasma proteins         | Type 2 diabetes without microangiopathy versus healthy subjects | ↑      | [61]      |
| Plasma proteins         | Type 2 diabetes with microangiopathy versus healthy subjects | ↑      | [61]      |
| Plasma proteins         | Type 2 diabetic patients versus age-matched controls   | ↑      | [49]      |
| Plasma proteins         | Childhood type 1 diabetes                              | ↑      | [62]      |
| Plasma proteins         | Diabetic patients without ulcer versus healthy subjects| ↑      | [63]      |
| Plasma proteins         | Diabetic patients with foot ulcer grade 1 versus healthy subjects | ↑      | [63]      |
| Plasma proteins         | Diabetic patients with foot ulcer grade 2 versus healthy subjects | ↑      | [63]      |
| Plasma proteins         | Diabetic patients versus healthy subjects              | ↑      | [64]      |
| Plasma proteins         | IGT subjects versus healthy subjects                  | ↑      | [64]      |
| Plasma proteins         | Diabetic type 2 patients versus healthy subjects       | ↑      | [65]      |
| Platelets               | Type 2 diabetes (young versus elderly)                 | ↑      | [66]      |
| Serum                   | Type 1 diabetic patients versus healthy subjects       | ↑      | [67]      |
| Serum                   | Diabetic patients versus healthy subjects              | ↑      | [68]      |
| Skin collagen           | Type 2 diabetes                                       | ↑      | [69]      |
| Subretinal fluid        | Diabetic patients versus control subjects              | ↑      | [70]      |

on the numerous evidence of a role of oxidative stress in the pathogenesis of vascular complications, the use of for example, antioxidants, uncouplers, or PARP inhibitors should represent an appealing approach. Candidate “drugs” include: vitamins A, C, and E, alpha-lipoic acid, SOD and catalase mimetics, L-propionyl carnitine, taurine, acetyl-L-carnitine, U83836E (a ROS scavenger), M40403 (a manganese superoxide dismutase mimetic), PKC-b inhibitors, peroxynitrite catalyst FP15, mitochondrial uncoupler DNP, PARP inhibitors, transketolase inhibitors, melatonin, statins, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, thiazolidinediones, synthetic pyridoximole antioxidant stobadine (STB), extracts from different natural sources (e.g., Artemisia campestris, Centaurium erythraea), the metal chelator pyrrolidine dithiocarbamate (PDTC), and plant polyphenols (e.g., myricetin), among others.

PARP inhibition may emerge as a novel approach for the prevention or reversal of diabetic complications. The benefits and potential risks associated with chronic administration of PARP inhibitors are discussed in a recent review [139]. The comparative therapeutic utility of PARP inhibition for the experimental therapy of diabetic complications should be explored by additional preclinical and subsequent clinical investigations. The development of uncoupling strategies is not forthcoming [93]. So, the time is upon us to test antioxidant therapies in diabetes [78, 93].
8. Conclusions

Hyperglycaemia is the first trigger in the pathogenesis of diabetic vascular complications and it activates many metabolic pathways and their downstream mediators. Several mitochondrial and other intracellular pathways are implicated in the increased production of oxidants. In subjects with diabetes, oxidative damage is enhanced and contributes to the development of endothelial dysfunction and vascular complications. Nevertheless, there still is a considerable wealth of knowledge to be acquired, concerning oxidative stress and diabetes. Assuming that oxidative stress has also a signalling role (exceeding the role of NO), how the signaling role of oxidative stress is modified by diabetic status is still an open question. It needs to be elucidated how the general increase of protein oxidative damage has an impact on the signalling modules of oxidative stress. Furthermore, with a wide knowledge on protein oxidative modification chemistry, there is still lacking a comprehensive study dissecating the potential pathways of protein oxidative modifications in diabetes and diabetes complications. Numerous antioxidant agents are being investigated and there is growing interest in developing new compounds specifically targeting oxidative stress. However, up to now, there is a lack of supporting evidence for an extensive use of antioxidants for preventing or treating diabetic vascular complications. A better and more precise knowledge of the molecular mechanisms underlying hyperglycaemia-related damage will help in developing better therapies. When the answer of these and other relevant questions will be available, then a rationale intervention on ROS homeostasis, more directed than the mere supplementation with antioxidants, will be granted for therapy of diabetes vascular complications.

Conflicts of Interests

The authors declare no conflict of interests.

Acknowledgments

The authors are grateful to the anonymous reviewers for criticisms and suggestions, which improved the paper. Investigations of the authors of this paper have been supported by Grants ref. BFI2003-01287, BFU2006-14495/BFI, and BFU2009-11879/BFI; Reticef RD06/0013/0012, and 2005SGR00101, and 2009SGR735 from the Ministry of Science and Innovation, Ministry of Health, and the Autonomous Government of Catalonia, respectively.

References

[1] D. M. Nathan, "Some answers, more controversy, from UKPDS," The Lancet, vol. 352, no. 9131, pp. 832–833, 1998.
[2] P. Reichard, B. Y. Nilsson, and U. Rosenqvist, "The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus," The New England Journal of Medicine, vol. 329, no. 5, pp. 304–309, 1993.
[3] C. W. Heilig, L. A. Concepcion, B. L. Riser et al., "Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype," Journal of Clinical Investigation, vol. 96, no. 4, pp. 1802–1814, 1995.
[4] N. Kaiser, S. Sasson, E. P. Feener et al., "Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells," Diabetes, vol. 42, no. 1, pp. 80–89, 1993.
[5] M. Brownlee, "The pathobiology of diabetic complications: a unifying mechanism," Diabetes, vol. 54, no. 6, pp. 1615–1625, 2005.
[6] T. Nishikawa, D. Edelstein, X. L. Du et al., "Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage," Nature, vol. 404, no. 6779, pp. 787–790, 2000.
[7] J. R. Treberg and M. D. Brand, "A model of the proton translocation mechanism of complex I," Journal of Biological Chemistry, vol. 286, no. 20, pp. 17579–17584, 2011.
[8] I. E. Scheffler, Mitochondria, Wiley-Liss, New York, NY, USA, 1999.
[9] F. Moien-Afshari, S. Ghosh, S. Elmi et al., "Exercise restores endothelial function independently of weight loss or hyperglycaemic status in db/db mice," Diabetologia, vol. 52, no. 1, p. 181, 2009.
[10] M. S. Parihar, M. Chaudhary, R. Shetty, and T. Hemnani, "Susceptibility of hippocampus and cerebral cortex to oxidative damage in streptozotocin treated mice: prevention by extracts of Withania somnifera and Aloe vera," Journal of Clinical Neuroscience, vol. 11, no. 4, pp. 397–402, 2004.
[11] S. Ghosh, M. Khazaee, F. Moien-Afshari et al., "Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in db/db mice," American Journal of Physiology, vol. 296, no. 4, pp. F700–F708, 2009.
[12] E. M. Olofsson, S. L. Marklund, and A. Behndig, "Enhanced diabetes-induced cataract in copper-zinc superoxide dismutase-null mice," Investigative Ophthalmology and Visual Science, vol. 50, no. 6, pp. 2913–2918, 2009.
[13] M. S. Bitar, S. Wahid, C. W. T. Pilcher, E. Al-Saleh, and F. Al-Mulla, "α-lipoic acid mitigates insulin resistance in Goto-Kakizaki rats," Hormone and Metabolic Research, vol. 36, no. 8, pp. 542–549, 2004.
[14] R. J. Waddington, A. Alraies, J. S. Colombo, A. J. Sloan, J. Okazaki, and R. Moseley, "Characterization of oxidative stress status during diabetic bone healing," Cells Tissues Organs, vol. 194, no. 2–4, pp. 307–312, 2011.
[15] B. V. Ramana, V. V. Kumar, P. N. R. Krishna, C. S. Kumar, P. U. M. Reddy, and T. N. Raju, "Effect of quercetin on galactose-induced hyperglycaemic oxidative stress in hepatic and neuronal tissues of Wistar rats," Acta Diabetologica, vol. 43, no. 4, pp. 135–141, 2006.
[16] S. Correia, C. Carvalho, M. S. Santos et al., "Metformin protects the brain against the oxidative imbalance promoted by type 2 diabetes," Medicinal Chemistry, vol. 4, no. 4, pp. 358–364, 2008.
[17] A. Cumaoğlu, G. Ozansoy, A. M. Irat, A. Aricioglu, C. Karasu, and N. Ari, "Effect of long term, non cholesterol lowering dose of fluvastatin treatment on oxidative stress in brain and peripheral tissues of streptozotocin-diabetic rats," European Journal of Pharmacology, vol. 654, no. 1, pp. 80–85, 2011.
[18] P. Suryanarayana, A. Satyanarayana, N. Balakrishna, P. U. Kumar, and G. Bhanuprakash Reddy, "Effect of turmeric and curcumin on oxidative stress and antioxidant enzymes..."
in streptozotocin-induced diabetic rat,” *Medical Science Monitor*, vol. 13, no. 12, pp. BR286–BR292, 2007.

[19] A. Shirpour, S. Salami, M. H. Khadem-Ansari, B. Ilkhanizadeh, F. G. Pakdel, and K. Khademvatani, “Cardioprotective effect of vitamin E: rescues of diabetes-induced cardiac dysfunction, oxidative stress, and apoptosis in rat,” *Journal of Diabetes and its Complications*, vol. 23, no. 5, pp. 310–316, 2009.

[20] S. R. Powell, S. M. Samuel, P. Wang et al., “Upregulation of myocardial 11S-activated proteasome in experimental hyperglycemia,” *Journal of Molecular and Cellular Cardiology*, vol. 44, no. 3, pp. 618–621, 2008.

[21] S. R. Powell, S. M. Samuel, P. Wang et al., “Upregulation of myocardial 11S-activated proteasome in experimental hyperglycemia,” *Journal of molecular and cellular cardiology*, vol. 44, no. 3, pp. 618–621, 2008.

[22] M. Roy, S. Sen, and A. S. Chakraborti, “Action of pelargoni- din on hyperglycemia and oxidative damage in diabetic rats: implication for glycation-induced hemoglobin modification,” *Life Sciences*, vol. 82, no. 21–22, pp. 1102–1110, 2008.

[23] V. Rajani Kanth, P. Uma Maheswara Reddy, and T. N. Raju, “Attenuation of streptozotocin-induced oxidative stress in hepatic and intestinal tissues of wistar rat by methanolic-garlic extract,” *Acta Diabetologica*, vol. 45, no. 4, pp. 243–251, 2008.

[24] R. Pamplona, V. Ayala, J. Boada, J. Serrano, and M. Portero-Otin, “Protein oxidative damage in diabetes,” in *Advances in Molecular Mechanisms and Pharmacology of Diabetic Complications*, M. Stefek, Ed., pp. 87–107, Research Signpost, Kerala, India, 2010.

[25] M. Portero-Otin, R. Pamplona, J. Boada et al., “Inhibition of renin angiotensin system decreases renal protein oxidative damage in diabetic rats,” *Biochemical and Biophysical Research Communications*, vol. 368, no. 3, pp. 528–535, 2008.

[26] A. Cumaoglu, M. Stefk, V. Bauer, N. Ari, A. Arcioglu, and C. Karasu, “Glycoxidative and nitrosative stress in kidney of experimental diabetic rats: effects of the pyrdoindole antioxidant stobadine,” *Neuroendocrinology Letters*, vol. 31, no. 3, pp. 313–318, 2010.

[27] Z. Kyselová, S. J. García, A. Gajdošíková, A. Gajdošík, and M. Stefk, “Temporal relationship between lens protein oxidation and cataract development in streptozotocin-induced diabetic rats,” *Physiological Research*, vol. 54, no. 1, pp. 49–56, 2005.

[28] M. Viana, O. I. Aruoma, E. Herrera, and B. Bonet, “Oxidative damage in pregnant diabetic rats and their embryos,” *Free Radical Biology and Medicine*, vol. 29, no. 11, pp. 1115–1121, 2000.

[29] A. Cumaoglu, Ç. Çevik, L. Rackova, N. Ari, and Ç. Karasu, “Effects of antioxidant stobadine on protein carbonylation, advanced oxidation protein products and reductive capacity of liver in streptozotocin-diabetic rats: role of oxidative/nitrosative stress,” *BioFactors*, vol. 30, no. 3, pp. 171–178, 2007.

[30] N. Altan, A. Sepici-Dinçel, D. Şahin, N. Kocamanoglu, F. Kosova, and A. Engin, “Oxidative DNA damage: the thyroid hormone-mediated effects of insulin on liver tissue,” *Endocrine*, vol. 38, no. 2, pp. 214–220, 2010.

[31] G. Eren, Z. Cukurova, O. Hergunsel et al., “Protective effect of the nuclear factor kappa B inhibitor pyrrolidine dithiocarbamate in lung injury in rats with streptozotocin-induced diabetes,” *Respiration*, vol. 79, no. 5, pp. 402–410, 2010.

[32] M. Sefi, H. Fetoui, M. Makni, and N. Zeghal, “Mitigating effects of antioxidant properties of Artemisia campestris leaf extract on hyperlipidemia, advanced glycation end products and oxidative stress in alloxan-induced diabetic rats,” *Food and Chemical Toxicology*, vol. 48, no. 7, pp. 1986–1993, 2010.

[33] M. Sefi, H. Fetoui, N. Lachkar et al., “Centaurium erythrea (Gentianacea) leaf extract alleviates streptozotocin-induced oxidative stress and β-cell damage in rat pancreas,” *Journal of Ethnopharmacology*, vol. 135, no. 2, pp. 243–250, 2011.

[34] R. H. Nagaraj, P. Sarkar, A. Mally, K. M. Biemel, M. O. Lederer, and P. S. Padayatti, “Effect of pyrrolidine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyrrolidine and methylglyoxal,” *Archives of Biochemistry and Biophysics*, vol. 402, no. 1, pp. 110–119, 2002.

[35] A. F. Fidan and Y. Dündar, “The effects of Yucca schidigera and Quillaja saponaria on DNA damage, protein oxidation, lipid peroxidation, and some biochemical parameters in streptozotocin-induced diabetic rats,” *Journal of Diabetes and its Complications*, vol. 22, no. 5, pp. 348–356, 2008.

[36] C. A. Y. Wayhs, V. Manfredini, A. Sitta et al., “Protein and lipid oxidative damage in streptozotocin-induced diabetic rats submitted to forced swimming test: the insulin and clonazepam effect,” *Metabolic Brain Disease*, vol. 25, no. 3, pp. 297–304, 2010.

[37] Y. Du, C. M. Miller, and T. S. Kern, “Hyperglycemia increases mitochondrial superoxide in retina and retinal cells,” *Free Radical Biology and Medicine*, vol. 35, no. 11, pp. 1491–1499, 2003.

[38] C. A. Haber, T. K. T. Lam, Z. Yu et al., “N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: possible role of oxidative stress,” *American Journal of Physiology*, vol. 285, no. 4, pp. E744–E753, 2003.

[39] M. Oh-Ishi, T. Ueno, and T. Maeda, “Proteomic method detects oxidatively induced protein carbonyls in muscles of a diabetes model Otsuka Long-Evans Tokushima Fatty (OLETF) rat,” *Free Radical Biology and Medicine*, vol. 34, no. 1, pp. 11–22, 2003.

[40] E. A. Muenlenbach, C. J. Diehl, M. K. Teachey et al., “Interactions of the advanced glycation end product inhibitor pyrrolidine and the antioxidant α-lipoic acid on insulin resistance in the obese Zucker rat,” *Metabolism*, vol. 57, no. 10, pp. 1465–1472, 2008.

[41] O. Kurt, T. Y. Özden, N. Ozsoy et al., “Influence of vanadium supplementation on oxidative stress factors in the muscle of STZ-diabetic rats,” *BioMetals*, vol. 24, no. 5, pp. 943–949, 2011.

[42] B. Shrilatha and Muralidhara, “Early oxidative stress in testis and epididymal sperm in streptozotocin-induced diabetic mice: its progression and genotoxic consequences,” *Reproductive Toxicology*, vol. 23, no. 4, pp. 578–587, 2007.

[43] N. K. Fukagawa, M. Li, C. R. Timblin, and B. T. Mossman, “Modulation of cell injury and survival by high glucose and advancing age,” *Free Radical Biology and Medicine*, vol. 31, no. 12, pp. 1560–1569, 2001.

[44] A. Gumieniczek, H. Hopkala, J. Roliński, and A. Bojarska-Junak, “Antioxidative and anti-inflammatory effects of res-eglimate in plasma of diabetic animals,” *Pharmaceutical Research*, vol. 52, no. 2, pp. 162–166, 2005.

[45] A. K. Jain, G. Lim, M. Langford, and S. K. Jain, “Effect of high-glucose levels on protein oxidation in cultured lens cells, and in crystalline and albumin solution and its inhibition by vitamin B6 and N-acetylcysteine: its possible relevance to cataract formation in diabetes,” *Free Radical Biology and Medicine*, vol. 33, no. 12, pp. 1615–1621, 2002.
[46] A. Constantin, E. Constantinescu, M. Dumitrescu, A. Calin, and D. Popov, "Effects of ageing on carbonyl stress and antioxidant defense in RBCs of obese type 2 diabetic patients," *Journal of Cellular and Molecular Medicine*, vol. 9, no. 3, pp. 683–691, 2005.

[47] K. B. Pandey, N. Mishra, and S. I. Rizvi, "Myricetin may provide protection against oxidative stress in type 2 diabetic erythrocytes," *Zeitschrift fur Naturforschung Section C*, vol. 64, no. 9-10, pp. 626–630, 2009.

[48] D. Komukglu, G. D. Kemerli, T. Sabuncu, and H. H. Hatemi, "Protein carbonyl content in erythrocyte membranes in type 2 diabetic patients," *Hormone and Metabolic Research*, vol. 34, no. 7, pp. 367–370, 2002.

[49] V. Calabrese, C. Mancuso, M. Sapienza et al., "Oxidative stress and cellular stress response in diabetic nephropathy," *Cell Stress and Chaperones*, vol. 12, no. 4, pp. 299–306, 2007.

[50] S. Belia, F. Santilli, S. Beccafico et al., "Oxidative-induced membrane damage in diabetes lymphocytes: effects on intracellular Ca²⁺ homeostasis," *Free Radical Research*, vol. 43, no. 2, pp. 138–148, 2009.

[51] M. T. Coughlan, P. P. Verhaar, M. Permezel, H. M. Georgiou, and G. E. Rice, "Altered placental oxidative stress status in gestational diabetes mellitus," *Placenta*, vol. 25, no. 1, pp. 78–84, 2004.

[52] P. Odetti, S. Garibaldi, G. Noberasco et al., "Levels of carbonyl groups in plasma proteins of type 2 diabetes mellitus subjects," *Acta Diabetologica*, vol. 36, no. 4, pp. 179–183, 1999.

[53] T. Duñate, A. Herreros, E. Martínez et al., "Protein oxidative stress in dialysis patients," *Advances in Peritoneal Dialysis*, vol. 18, pp. 15–17, 2002.

[54] R. De Cristofaro, B. Rocca, E. Vitacolonna et al., "Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus," *Journal of Thrombosis and Haemostasis*, vol. 1, no. 2, pp. 250–256, 2003.

[55] P. Martín-Gallán, A. Carrascosa, M. Gussinyé, and C. Domínguez, "Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications," *Free Radical Biology and Medicine*, vol. 34, no. 12, pp. 1563–1574, 2003.

[56] B. P. Oberg, E. McMenamin, F. L. Lucas et al., "Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease," *Kidney International*, vol. 65, no. 3, pp. 1009–1016, 2004.

[57] A. Saha, S. Adak, S. Chowdhury, and M. Bhattacharyya, "Enhanced oxygen releasing capacity and oxidative stress in diabetes mellitus and diabetes mellitus-associated cardiovascular disease: a comparative study," *Clinica Chimica Acta*, vol. 361, no. 1–2, pp. 141–149, 2005.

[58] U. Çakatay, "Protein oxidation parameters in type 2 diabetic patients with good and poor glycaemic control," *Diabetes and Metabolism*, vol. 31, no. 6, pp. 551–557, 2005.

[59] G. Kalogerakis, A. M. Baker, S. Christov et al., "Oxidative stress and high-density lipoprotein function in type 1 diabetes and end-stage renal disease," *Clinical Science*, vol. 108, no. 6, pp. 497–506, 2005.

[60] V. A. Cameron, T. J. Mocatta, A. P. Pilbrow et al., "Angiotesin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure," *Hypertension*, vol. 47, no. 6, pp. 1155–1161, 2006.

[61] A. Adakakalakoteswari, M. Rema, V. Mohan, and M. Balasubramanyam, "Oxidative DNA damage and augmentation of poly(ADP-ribose) polymerase/nuclear factor-kappa B signaling in patients with type 2 diabetes and microangiopathy," *International Journal of Biochemistry and Cell Biology*, vol. 39, no. 9, pp. 1673–1684, 2007.

[62] P. Martín-Gallán, A. Carrascosa, M. Gussinyé, and C. Domínguez, "Changes in oxidant-antioxidant status in young diabetic patients from clinical onset onwards," *Journal of Cellular and Molecular Medicine*, vol. 11, no. 6, pp. 1352–1366, 2007.

[63] R. Rattan and D. Nayak, "High levels of plasma malondialdehyde, protein carbonyl, and fibrinogen have prognostic potential to predict poor outcomes in patients with diabetic foot wounds: a preliminary communication," *International Journal of Lower Extremity Wounds*, vol. 7, no. 4, pp. 198–203, 2008.

[64] K. Gokulakrishnan, K. T. Mohanavalli, F. Monickaraj, V. Mohan, and M. Balasubramanyam, "Subclinical inflammation/oxidation as revealed by altered gene expression profiles in subjects with impaired glucose tolerance and type 2 diabetes patients," *Molecular and Cellular Biochemistry*, vol. 324, no. 1-2, pp. 173–181, 2009.

[65] F. Zheng, W. Lu, C. Jia, H. Li, Z. Wang, and W. Jia, "Relationships between glucose excursion and the activation of oxidative stress in patients with newly diagnosed type 2 diabetes or impaired glucose regulation," *Endocrine*, vol. 37, no. 1, pp. 201–208, 2010.

[66] N. Alexandru, A. Constantin, and D. Popov, "Carboxylation of platelet proteins occurs as consequence of oxidative stress and thrombin activation, and is stimulated by ageing and type 2 diabetes," *Clinical Chemistry and Laboratory Medicine*, vol. 46, no. 4, pp. 528–536, 2008.

[67] Z. Rasheed and R. Ali, "Reactive oxygen species damaged human serum albumin in patients with type 1 diabetes mellitus: biochemical and immunological studies," *Life Sciences*, vol. 79, no. 24, pp. 2320–2328, 2006.

[68] H. Z. Pan, L. Zhang, M. Y. Guo et al., "The oxidative stress status in diabetes mellitus and diabetic nephropathy," *Acta Diabetologica*, vol. 47, pp. 71–76, 2009.

[69] D. R. Sell, M. A. Lane, W. A. Johnson et al., "Longevity and the genetic determination of collagen glyoxidation kinetics in mammalian senescence," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 1, pp. 485–490, 1996.

[70] I. Grattagliano, G. Vendemiale, F. Boscia, T. Micelli-Ferrari, L. Cardia, and E. Altomare, "Oxidative retinal products and ocular damages in diabetic patients," *Free Radical Biology and Medicine*, vol. 25, no. 3, pp. 369–372, 1998.

[71] A. Boveris and B. Chance, "The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen," *Biochemical Journal*, vol. 134, no. 3, pp. 707–716, 1973.

[72] B. Chance, H. Sies, and A. Boveris, "Hydroperoxide metabolism in mammalian organs," *Physiological Reviews*, vol. 59, no. 3, pp. 527–605, 1979.

[73] H. J. Forman and J. A. Kennedy, "Role of superoxide radical in mitochondrial dehydrogenase reactions," *Biochemical and Biophysical Research Communications*, vol. 60, no. 3, pp. 1044–1050, 1974.

[74] G. Loschen, A. Azzi, C. Richter, and L. Flohe, "Superoxide radicals as precursors of mitochondrial hydrogen peroxide," *FEBS Letters*, vol. 42, no. 1, pp. 68–72, 1974.

[75] G. Loschen, L. Flohé, and B. Chance, "Respiratory chain linked H₂O₂ production in pigeon heart mitochondria," *FEBS Letters*, vol. 18, no. 2, pp. 261–264, 1971.
a theoretical assessment,” *Free Radical Biology and Medicine*, vol. 31, no. 10, pp. 1208–1215, 2001.

[77] A. van der Vliet, J. P. Eisicher, B. Halliwell, and C. E. Cross, “Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite: a potential additional mechanism of nitric oxide-dependent toxicity,” *Journal of Biological Chemistry*, vol. 272, no. 12, pp. 7617–7625, 1997.

[78] Z. Mokini, M. L. Marcovecchio, and F. Chiarelli, “Molecular pathology of oxidative stress in diabetic angiopathy: role of mitochondrial and cellular pathways,” *Diabetes Research and Clinical Practice*, vol. 87, no. 3, pp. 313–321, 2010.

[79] G. Barja and A. Herrero, “Localization at complex I and mechanism of the higher free radical production of brain nonsynaptic mitochondria in the short-lived rat than in the long-lived pigeon,” *Journal of Bioenergetics and Biomembranes*, vol. 30, no. 3, pp. 235–243, 1998.

[80] Y. R. Chen, C. L. Chen, L. Zhang, K. B. Green-Church, and J. L. Zweier, “Superoxide generation from mitochondrial NADH dehydrogenase induces self-inactivation with specific protein radical formation,” *Journal of Biological Chemistry*, vol. 280, no. 45, pp. 37339–37348, 2005.

[81] M. L. Genova, B. Ventura, G. Giuliani et al., “The site of is not a bound ubisemiquinone but presumably iron-sulfur cluster N2,” *FEBS Letters*, vol. 505, no. 3, pp. 356–368, 2001.

[82] A. Herrero and G. Barja, “Sites and mechanisms responsible for the low rate of free radical production of heart mitochondria in the long-lived pigeon,” *Mechanisms of Ageing and Development*, vol. 98, no. 2, pp. 95–111, 1997.

[83] A. P. Kudin, N. Y. B. Bimpong-Buta, S. Vielhaber, C. E. Elger, and W. S. Kunz, “Characterization of superoxide-producing sites in isolated brain mitochondria,” *Journal of Biological Chemistry*, vol. 279, no. 6, pp. 4127–4135, 2004.

[84] Y. Kushnareva, A. N. Murphy, and A. Andreyev, “Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation-reduction state,” *Biochemical Journal*, vol. 368, no. 2, pp. 545–553, 2002.

[85] A. I. Lambert and M. D. Brand, “Inhibitors of the quinone-binding site allow rapid superoxide production from mitochondrial NADH-ubiquinone oxidoreductase (complex I),” *Journal of Biological Chemistry*, vol. 279, no. 38, pp. 39414–39420, 2004.

[86] T. Ohnishi, J. E. Johnson, T. Yano, R. Lobrutto, and W. R. Widger, “Thermodynamic and EPR studies of slowly relaxing ubisemiquinone species in the isolated bovine heart complex I,” *FEBS Letters*, vol. 579, no. 2, pp. 500–506, 2005.

[87] A. Boveris, E. Cadenas, and A. O. M. Stoppani, “Role of ubiquinone in the mitochondrial generation of hydrogen peroxide,” *Biochemical Journal*, vol. 156, no. 2, pp. 435–444, 1976.

[88] I. St-Pierre, J. A. Buckingham, S. J. Roebuck, and M. D. Brand, “Topology of superoxide production from different sites in the mitochondrial electron transport chain,” *Journal of Biological Chemistry*, vol. 277, no. 47, pp. 44784–44790, 2002.

[89] M. D. Brand, C. Aflourit, T. C. Esteves et al., “Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins,” *Free Radical Biology and Medicine*, vol. 37, no. 6, pp. 755–767, 2004.

[90] M. D. Brand, “The sites and topology of mitochondrial superoxide production,” *Experimental Gerontology*, vol. 45, no. 7-8, pp. 466–472, 2010.

[91] W. J. H. Koopman, L. G. J. Nijtmans, C. E. J. Dieteren et al., “Mammalian mitochondrial complex I: biogenesis, regulation, and reactive oxygen species generation,” *Antioxidants and Redox Signaling*, vol. 12, no. 12, pp. 1431–1470, 2010.

[92] G. Lenaz, R. Fato, M. L. Genova, C. Bergamini, C. Bianchi, and A. Biondi, “Mitochondrial Complex I: structural and functional aspects,” *Biochimica et Biophysica Acta*, vol. 1757, no. 9-10, pp. 1406–1420, 2006.

[93] M. P. Murphy, “How mitochondria produce reactive oxygen species,” *Biochemical Journal*, vol. 417, no. 1, pp. 1–13, 2009.

[94] R. Pamplona and G. Barja, “Aging rate, free radical production, and constitutive sensitivity to lipid peroxidation: insights from comparative studies,” in *Aging at the Molecular Level*, T. Van Zglinicki, Ed., vol. 1 of *Biology of Aging and Its Modulation Series*, pp. 47–64, Kluwer Academic Publishers, New York, NY, USA, 2003.

[95] R. Pamplona and G. Barja, “Mitochondrial oxidative stress, aging and caloric restriction: the protein and methionine connection,” *Biochimica et Biophysica Acta*, vol. 1757, no. 5-6, pp. 496–508, 2006.

[96] R. Stefanatos and A. Sanz, “Mitochondrial complex I: a central regulator of the aging process,” *Cell Cycle*, vol. 10, no. 10, pp. 1528–1532, 2011.

[97] J. R. Treberg, C. L. Quinlan, and M. D. Brand, “Evidence for two sites of superoxide production by mitochondrial NADH-ubiquinone oxidoreductase (complex I),” *Journal of Biological Chemistry*, vol. 286, no. 31, pp. 27103–27110, 2011.

[98] G. Barja, “Mitochondrial oxygen consumption and reactive oxygen species production are independently modulated: implications for aging studies,” *Rejuvenation Research*, vol. 10, no. 2, pp. 215–223, 2007.

[99] R. Pamplona and D. Costantini, “Molecular and structural antioxidant defences against oxidative stress in animals,” *American Journal of Physiology*, vol. 301, no. 4, pp. R843–R863, 2011.

[100] K. S. Echtay, T. C. Esteves, J. L. Pakay et al., “A signalling role for 4-hydroxy-2-nonenal in regulation of mitochondrial uncoupling,” *The EMBO Journal*, vol. 22, no. 16, pp. 4103–4110, 2003.

[101] A. Sanz, G. Barja, R. Pamplona, and C. Leeuwenburgh, “Free radicals and mammalian aging,” in *Redox Signalling and Regulation in Biology and Medicine*, C. Jacob and P. G. Winyard, Eds., pp. 433–472, Wiley-VCH Verlag GmbH & Co., Weinheim, Germany, 2008.

[102] X. Du, T. Matsumura, D. Edelstein et al., “Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells,” *Journal of Clinical Investigation*, vol. 112, no. 7, pp. 1049–1057, 2003.

[103] A. Bürkle, “Poly(ADP-ribose): the most elaborate metabolite of NAD”, *The FEBS Journal*, vol. 272, no. 18, pp. 4576–4589, 2005.

[104] C. Colussi, M. C. Albertini, S. Coppola, S. Rovidati, F. Galli, and L. Ghibelli, “H2O2-induced block of glycolysis as an active ADP-ribsylation reaction protecting cells from apoptosis,” *FASEB Journal*, vol. 14, no. 14, pp. 2266–2276, 2000.

[105] J. Diefenbach and A. Bürkle, “Introduction to poly(ADP-ribose) metabolism,” *Cellular and Molecular Life Sciences*, vol. 62, no. 7-8, pp. 721–730, 2005.

[106] S. Beneke and A. Bürkle, “Survey and summary: poly(ADP-ribsylation) in mammalian ageing,” *Nucleic Acids Research*, vol. 35, no. 22, pp. 7456–7465, 2007.
References

[107] B. Halliwell and J. M. C. Gutteridge, *Free Radicals in Biology and Medicine*, Oxford University Press, Oxford, UK, 2007.

[108] R. Pamplona, “Membrane phospholipids, lipoxidative damage and molecular integrity: a causal role in aging and longevity,” *Biochimica et Biophysica Acta*, vol. 1777, no. 10, pp. 1249–1262, 2008.

[109] M. Portero-Otin and R. Pamplona, “Is endogenous oxidative protein damage involved in the aging process?” in *Protein Oxidation and Disease*, J. Pietzsch, Ed., pp. 91–142, Research Signpost, Kerala, India, 2006.

[110] M. Conrad, M. Schneider, A. Seiler, and G. W. Bornkamm, “Physiological role of phospholipid hydroperoxide glutathione peroxidase in mammals,” *Biological Chemistry*, vol. 388, no. 10, pp. 1019–1025, 2007.

[111] D. A. Bota and K. J. A. Davies, “Protein degradation in mitochondria: implications for oxidative stress, aging and disease: a novel etiological classification of mitochondrial proteolytic disorders,” *Mitochondrion*, vol. 1, no. 1, pp. 33–49, 2001.

[112] R. Geredilla, V. A. Bohr, and T. Stevnsner, “Mitochondrial DNA repair and association with aging—an update,” *Experimental Gerontology*, vol. 45, no. 7–8, pp. 478–488, 2010.

[113] S. Hofmann and M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications: a unifying mechanism,” in *Diabetes Mellitus: A Fundamental and Clinical Text*, D. LeRoith, S. I. Taylor, and M. J. Olefsky, Eds., pp. 1441–1457, Lippincott Williams & Wilkins, Philadelphia, PA, USA, 3rd edition, 2004.

[114] C. Affourtit and M. D. Brand, “On the role of uncoupling protein-2 in pancreatic beta cells,” *Biochimica et Biophysica Acta*, vol. 1777, no. 7–8, pp. 973–979, 2008.

[115] Z. Xie, J. Zhang, J. Wu, B. Viollet, and M. H. Zou, “Upregulation of mitochondrial uncoupling protein-2 by the AMP-Activated protein kinase in endothelial cells attenuates oxidative stress in diabetes,” *Diabetes*, vol. 57, no. 12, pp. 3222–3230, 2008.

[116] X. L. Du, D. Edelstein, L. Rossetti et al., “Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 22, pp. 12222–12226, 2000.

[117] A. V. Cantero, M. Portero-Otin, V. Ayala et al., “Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-β: implications for diabetic atherosclerosis,” *FASEB Journal*, vol. 21, no. 12, pp. 3096–3106, 2007.

[118] A. Negre-Salvayre, R. Salvayre, N. Augé, R. Pamplona, and M. Portero-Otin, “Hyperglycemia and glycation in diabetic complications,” *Antioxidants and Redox Signaling*, vol. 11, no. 12, pp. 3071–3109, 2009.

[119] M. Portero-Otin, R. Pamplona, M. J. Bellmunt et al., “Advanced glycation end product precursors impair epidermal growth factor receptor signaling,” *Diabetes*, vol. 51, no. 5, pp. 1535–1542, 2002.

[120] K. V. Ramana, B. Friedrich, R. Tammali, M. B. West, A. Bhatnagar, and S. K. Srivastava, “Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells,” *Diabetes*, vol. 54, no. 3, pp. 818–829, 2005.

[121] S. S. M. Chung, E. C. M. Ho, K. S. L. Lam, and S. K. Chung, “Contribution of polyol pathway to diabetes-induced oxidative stress,” *Journal of the American Society of Nephrology*, vol. 14, no. 5, pp. S233–S236, 2003.

[122] S. Srivastava, K. V. Ramana, R. Tammali, S. K. Srivastava, and A. Bhatnagar, “Contribution of aldose reductase to diabetic hyperproliferation of vascular smooth muscle cells,” *Diabetes*, vol. 55, no. 4, pp. 901–910, 2006.

[123] E. Toth, A. Racz, J. Toth et al., “Contribution of polyol pathway to arteriolar dysfunction in hyperglycemia. Role of oxidative stress, reduced NO, and enhanced PGH2/TXA2 mediation,” *American Journal of Physiology*, vol. 293, no. 5, pp. H3096–H3104, 2007.

[124] P. Pacher and C. Szabó, “Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme,” *Antioxidants and Redox Signaling*, vol. 7, no. 11–12, pp. 1568–1580, 2005.

[125] R. T. Dean, S. Fu, R. Stocker, and M. J. Davies, “Biochemistry and pathology of radical-mediated protein oxidation,” *Biochemical Journal*, vol. 324, no. 1, pp. 1–18, 1997.

[126] C. L. Hawkins and M. J. Davies, “Generation and propagation of radical reactions on proteins,” *Biochimica et Biophysica Acta*, vol. 1504, no. 2–3, pp. 196–219, 2001.

[127] R. L. Levine, L. Mosoni, B. S. Berlett, and E. R. Stadtman, “Methionine residues as endogenous antioxidants in proteins,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 26, pp. 15036–15040, 1996.

[128] E. R. Stadtman and R. L. Levine, “Free radical-mediated oxidation of free amino acids and amino acid residues in proteins,” *Amino Acids*, vol. 25, no. 3–4, pp. 207–218, 2003.

[129] E. R. Stadtman, “Protein oxidation and aging,” *Science*, vol. 257, no. 5074, pp. 1220–1224, 1992.

[130] S. R. Thorpe and J. W. Baynes, “Maillard reaction products in tissue proteins: new products and new perspectives,” *Amino Acids*, vol. 25, no. 3–4, pp. 275–281, 2003.

[131] I. Dalle-Donne, D. Giustarini, R. Colombo, R. Rossi, and A. Milzani, “Protein carboxylation in human diseases,” *Trends in Molecular Medicine*, vol. 9, no. 4, pp. 169–176, 2003.

[132] J. R. Requena, C. C. Chao, R. L. Levine, and E. R. Stadtman, “Glutamic and aminoadipic semialdehydes are the main carbonyl products of metal-catalyzed oxidation of proteins,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 1, pp. 69–74, 2001.

[133] R. Radi, A. Cassina, R. Hodara, C. Quijano, and L. Castro, “Peroxynitrite reactions and formation in mitochondria,” *Free Radical Biology and Medicine*, vol. 33, no. 11, pp. 1451–1464, 2002.

[134] A. J. Gow, D. Duran, S. Malcolm, and H. Ischiropoulos, “Effects of peroxynitrite-induced protein modifications on tyrosine phosphorylation and degradation,” *FEBS Letters*, vol. 385, no. 1–2, pp. 63–66, 1996.

[135] M. Tien, B. S. Berlett, R. L. Levine, P. B. Chock, and E. R. Stadtman, “Peroxynitrite-mediated modification of proteins at physiological carbon dioxide concentration: pH dependence of carbonyl formation, tyrosine nitration, and methionine oxidation,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 14, pp. 7809–7814, 1999.

[136] H. Rubbo, A. Denicola, and R. Radi, “Peroxynitrite inactivates thiol-containing enzymes of Trypanosoma cruzi energetic metabolism and inhibits cell respiration,” *Archives of Biochemistry and Biophysics*, vol. 308, no. 1, pp. 96–102, 1994.

[137] G. Staubauer, A. Giuffré, and P. Sarti, “Mechanism of S-nitrosothiol formation and degradation mediated by copper ions,” *Journal of Biological Chemistry*, vol. 274, no. 40, pp. 28128–28133, 1999.
[138] R. I. Viner, T. D. Williams, and C. Schöneich, “Peroxynitrite modification of protein thiols: oxidation, nitrosylation, and S-gluthiolation of functionally important cysteine residue(s) in the sarcoplasmic reticulum Ca-ATPase,” Biochemistry, vol. 38, no. 38, pp. 12408–12415, 1999.

[139] G. J. Southan and C. Szabó, “Poly(ADP-ribose) polymerase inhibitors,” Current Medicinal Chemistry, vol. 10, pp. 321–340, 2003.